Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 74 | 2024 | 11221 | 3.150 |
Why?
|
Receptors, Androgen | 15 | 2023 | 1083 | 2.270 |
Why?
|
Chromosomes, Human, Pair 8 | 7 | 2010 | 453 | 1.120 |
Why?
|
Androgen Antagonists | 17 | 2024 | 1421 | 0.870 |
Why?
|
Prostate | 10 | 2023 | 1781 | 0.840 |
Why?
|
Polymorphism, Single Nucleotide | 31 | 2024 | 16028 | 0.830 |
Why?
|
Carcinoma, Renal Cell | 14 | 2024 | 3200 | 0.790 |
Why?
|
Germ-Line Mutation | 6 | 2022 | 1885 | 0.740 |
Why?
|
Gene Expression Regulation, Neoplastic | 19 | 2024 | 8634 | 0.730 |
Why?
|
Neoplasms, Hormone-Dependent | 6 | 2015 | 410 | 0.700 |
Why?
|
Prostate-Specific Antigen | 15 | 2024 | 2487 | 0.690 |
Why?
|
Genetic Predisposition to Disease | 29 | 2024 | 18048 | 0.660 |
Why?
|
Telomerase | 1 | 2024 | 752 | 0.620 |
Why?
|
Kidney Neoplasms | 12 | 2024 | 4303 | 0.590 |
Why?
|
Genes, BRCA2 | 2 | 2021 | 592 | 0.490 |
Why?
|
Prostatectomy | 13 | 2024 | 1841 | 0.470 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 3 | 2021 | 165 | 0.470 |
Why?
|
Carboplatin | 1 | 2017 | 799 | 0.450 |
Why?
|
Genome-Wide Association Study | 20 | 2024 | 12778 | 0.410 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2021 | 1536 | 0.400 |
Why?
|
Enhancer Elements, Genetic | 7 | 2021 | 1368 | 0.390 |
Why?
|
Epigenomics | 6 | 2024 | 959 | 0.390 |
Why?
|
Male | 105 | 2024 | 364902 | 0.380 |
Why?
|
Watchful Waiting | 1 | 2015 | 499 | 0.380 |
Why?
|
Organic Anion Transporters | 4 | 2017 | 101 | 0.380 |
Why?
|
Prostatic Secretory Proteins | 1 | 2010 | 24 | 0.370 |
Why?
|
Radium | 2 | 2024 | 72 | 0.370 |
Why?
|
Androgens | 7 | 2024 | 1285 | 0.360 |
Why?
|
Quantitative Trait Loci | 8 | 2024 | 2127 | 0.350 |
Why?
|
Nuclear Receptor Coactivators | 1 | 2010 | 62 | 0.350 |
Why?
|
Thyroid Neoplasms | 1 | 2024 | 2360 | 0.350 |
Why?
|
Proto-Oncogene Proteins c-myc | 4 | 2022 | 998 | 0.340 |
Why?
|
Genes, myc | 2 | 2022 | 391 | 0.340 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2010 | 277 | 0.340 |
Why?
|
Adenocarcinoma | 6 | 2021 | 6406 | 0.340 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2923 | 0.330 |
Why?
|
Cell Line, Tumor | 16 | 2022 | 17135 | 0.320 |
Why?
|
Genetic Association Studies | 7 | 2021 | 2742 | 0.310 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 567 | 0.310 |
Why?
|
DNA, Neoplasm | 2 | 2011 | 1748 | 0.310 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2023 | 277 | 0.300 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2022 | 342 | 0.290 |
Why?
|
BRCA1 Protein | 4 | 2023 | 1155 | 0.280 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2022 | 2846 | 0.280 |
Why?
|
BRCA2 Protein | 3 | 2023 | 802 | 0.280 |
Why?
|
Humans | 118 | 2024 | 768393 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 11854 | 0.260 |
Why?
|
DNA Methylation | 6 | 2024 | 4421 | 0.250 |
Why?
|
Melanoma | 2 | 2024 | 5705 | 0.250 |
Why?
|
Alleles | 10 | 2023 | 6892 | 0.240 |
Why?
|
Neuroendocrine Tumors | 2 | 2022 | 658 | 0.240 |
Why?
|
DNA Repair | 4 | 2023 | 2048 | 0.240 |
Why?
|
Neoplasm Metastasis | 9 | 2019 | 4921 | 0.230 |
Why?
|
Genetic Loci | 4 | 2017 | 2630 | 0.230 |
Why?
|
Brachytherapy | 4 | 2019 | 1226 | 0.230 |
Why?
|
Precancerous Conditions | 1 | 2010 | 984 | 0.220 |
Why?
|
Leuprolide | 2 | 2024 | 313 | 0.210 |
Why?
|
Promoter Regions, Genetic | 3 | 2024 | 5801 | 0.210 |
Why?
|
Oncogene Protein p55(v-myc) | 1 | 2021 | 5 | 0.200 |
Why?
|
Epigenesis, Genetic | 5 | 2024 | 3827 | 0.200 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2021 | 37 | 0.190 |
Why?
|
Thiohydantoins | 1 | 2021 | 19 | 0.190 |
Why?
|
Prognosis | 15 | 2022 | 30022 | 0.190 |
Why?
|
Disease Progression | 13 | 2021 | 13646 | 0.180 |
Why?
|
Antineoplastic Agents | 6 | 2021 | 13697 | 0.180 |
Why?
|
Chromosome Mapping | 4 | 2020 | 4622 | 0.170 |
Why?
|
Estrogens | 1 | 2007 | 1534 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2024 | 9433 | 0.170 |
Why?
|
Survival Rate | 12 | 2024 | 12870 | 0.170 |
Why?
|
Prednisone | 2 | 2024 | 1567 | 0.170 |
Why?
|
Chromatin | 5 | 2023 | 2968 | 0.170 |
Why?
|
Mediator Complex Subunit 1 | 1 | 2019 | 31 | 0.170 |
Why?
|
Allelic Imbalance | 1 | 2020 | 77 | 0.170 |
Why?
|
Hemibody Irradiation | 1 | 2019 | 4 | 0.170 |
Why?
|
Genetic Counseling | 1 | 2023 | 634 | 0.160 |
Why?
|
Ribonucleoside Diphosphate Reductase | 1 | 2019 | 31 | 0.160 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 3252 | 0.160 |
Why?
|
Phenylenediamines | 1 | 2019 | 88 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 211 | 0.160 |
Why?
|
Aged | 39 | 2024 | 171562 | 0.160 |
Why?
|
Mutation | 8 | 2024 | 30228 | 0.150 |
Why?
|
Progesterone Reductase | 1 | 2018 | 14 | 0.150 |
Why?
|
Steroid Isomerases | 1 | 2018 | 19 | 0.150 |
Why?
|
Genotype | 13 | 2019 | 13042 | 0.150 |
Why?
|
Middle Aged | 42 | 2024 | 223491 | 0.150 |
Why?
|
Urogenital Neoplasms | 1 | 2019 | 133 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 7 | 2018 | 6541 | 0.140 |
Why?
|
Biomarkers, Pharmacological | 1 | 2018 | 162 | 0.140 |
Why?
|
Taxoids | 2 | 2017 | 668 | 0.140 |
Why?
|
Cohort Studies | 16 | 2021 | 41795 | 0.140 |
Why?
|
Extracellular Matrix Proteins | 1 | 2021 | 835 | 0.140 |
Why?
|
Ubiquitin Thiolesterase | 3 | 2021 | 462 | 0.140 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2020 | 792 | 0.130 |
Why?
|
Neoplasm Staging | 8 | 2018 | 11254 | 0.130 |
Why?
|
Neoplasm Invasiveness | 5 | 2017 | 3633 | 0.130 |
Why?
|
Transcription Factors | 5 | 2023 | 12166 | 0.130 |
Why?
|
Urologic Neoplasms | 1 | 2019 | 319 | 0.130 |
Why?
|
Inservice Training | 1 | 2018 | 375 | 0.130 |
Why?
|
Drug Administration Schedule | 3 | 2015 | 4859 | 0.130 |
Why?
|
Biological Transport | 2 | 2017 | 2085 | 0.120 |
Why?
|
Neoplasms | 4 | 2023 | 22385 | 0.120 |
Why?
|
Gonadotropin-Releasing Hormone | 3 | 2011 | 1149 | 0.120 |
Why?
|
Tuberculosis, Pulmonary | 2 | 2001 | 846 | 0.120 |
Why?
|
Multienzyme Complexes | 1 | 2018 | 665 | 0.120 |
Why?
|
Orchiectomy | 3 | 2011 | 466 | 0.120 |
Why?
|
Kallikreins | 1 | 2015 | 219 | 0.120 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2015 | 370 | 0.120 |
Why?
|
Germ Cells | 3 | 2023 | 643 | 0.110 |
Why?
|
Cancer Care Facilities | 1 | 2017 | 424 | 0.110 |
Why?
|
Genetic Variation | 4 | 2018 | 6606 | 0.110 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2019 | 755 | 0.110 |
Why?
|
Disease-Free Survival | 4 | 2018 | 6856 | 0.110 |
Why?
|
Inheritance Patterns | 1 | 2016 | 344 | 0.110 |
Why?
|
Pneumonectomy | 1 | 2001 | 1158 | 0.110 |
Why?
|
Survival Analysis | 5 | 2021 | 10117 | 0.110 |
Why?
|
Video Recording | 1 | 2019 | 974 | 0.110 |
Why?
|
RNA Interference | 3 | 2021 | 2836 | 0.110 |
Why?
|
Superoxide Dismutase | 1 | 2016 | 595 | 0.110 |
Why?
|
Aged, 80 and over | 15 | 2024 | 59686 | 0.110 |
Why?
|
Cell Proliferation | 4 | 2019 | 10478 | 0.110 |
Why?
|
Phenylthiohydantoin | 3 | 2020 | 208 | 0.100 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2019 | 799 | 0.100 |
Why?
|
Testosterone | 5 | 2024 | 2493 | 0.100 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2015 | 855 | 0.100 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2012 | 30 | 0.100 |
Why?
|
PTEN Phosphohydrolase | 1 | 2018 | 1119 | 0.100 |
Why?
|
Acetylation | 3 | 2023 | 1053 | 0.100 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2001 | 939 | 0.100 |
Why?
|
Organic Cation Transport Proteins | 1 | 2012 | 61 | 0.100 |
Why?
|
Immunoblotting | 1 | 2015 | 1647 | 0.100 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2012 | 93 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2017 | 5336 | 0.100 |
Why?
|
Combined Modality Therapy | 5 | 2021 | 8562 | 0.100 |
Why?
|
Estradiol Dehydrogenases | 1 | 2011 | 16 | 0.100 |
Why?
|
Pyrophosphatases | 1 | 2012 | 142 | 0.100 |
Why?
|
Organic Anion Transporters, Sodium-Independent | 1 | 2011 | 28 | 0.090 |
Why?
|
Metabolomics | 1 | 2020 | 1674 | 0.090 |
Why?
|
Telomere | 1 | 2017 | 943 | 0.090 |
Why?
|
Radiotherapy | 1 | 2018 | 1509 | 0.090 |
Why?
|
HEK293 Cells | 1 | 2020 | 4291 | 0.090 |
Why?
|
Polymorphism, Genetic | 3 | 2012 | 4250 | 0.090 |
Why?
|
Linkage Disequilibrium | 4 | 2020 | 1998 | 0.090 |
Why?
|
Protein Binding | 2 | 2015 | 9343 | 0.090 |
Why?
|
Bone Neoplasms | 2 | 2024 | 2565 | 0.090 |
Why?
|
Cell Line | 3 | 2020 | 15597 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3981 | 0.090 |
Why?
|
Risk Factors | 15 | 2023 | 74962 | 0.090 |
Why?
|
Pyrimidines | 2 | 2019 | 3048 | 0.090 |
Why?
|
Retrospective Studies | 14 | 2022 | 81801 | 0.080 |
Why?
|
Estrogen Receptor beta | 1 | 2010 | 171 | 0.080 |
Why?
|
Colorectal Neoplasms | 1 | 2009 | 6971 | 0.080 |
Why?
|
Homeodomain Proteins | 2 | 2015 | 2429 | 0.080 |
Why?
|
Nitriles | 3 | 2020 | 984 | 0.080 |
Why?
|
Dehydroepiandrosterone Sulfate | 3 | 2015 | 241 | 0.080 |
Why?
|
TCF Transcription Factors | 1 | 2009 | 138 | 0.080 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2009 | 152 | 0.080 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2011 | 554 | 0.080 |
Why?
|
Benzamides | 3 | 2020 | 1380 | 0.080 |
Why?
|
Cluster Analysis | 1 | 2015 | 2728 | 0.080 |
Why?
|
Chemokine CCL2 | 1 | 2010 | 606 | 0.080 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 2812 | 0.070 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2009 | 419 | 0.070 |
Why?
|
Gonadal Steroid Hormones | 1 | 2011 | 708 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3520 | 0.070 |
Why?
|
Binding Sites | 1 | 2015 | 6017 | 0.070 |
Why?
|
RNA, Neoplasm | 1 | 2009 | 750 | 0.070 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39407 | 0.070 |
Why?
|
Adult | 19 | 2021 | 223640 | 0.070 |
Why?
|
Estrogen Receptor alpha | 1 | 2010 | 581 | 0.070 |
Why?
|
Genetic Diseases, Inborn | 1 | 2010 | 605 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2019 | 3617 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3236 | 0.060 |
Why?
|
Quality of Life | 3 | 2024 | 13503 | 0.060 |
Why?
|
Treatment Outcome | 10 | 2024 | 65379 | 0.060 |
Why?
|
Genetic Linkage | 1 | 2010 | 2342 | 0.060 |
Why?
|
Genome, Human | 3 | 2019 | 4450 | 0.060 |
Why?
|
DNA Primers | 1 | 2009 | 2825 | 0.060 |
Why?
|
Polymerase Chain Reaction | 2 | 2011 | 6085 | 0.060 |
Why?
|
MicroRNAs | 2 | 2011 | 3804 | 0.060 |
Why?
|
Sequence Analysis, DNA | 1 | 2015 | 4775 | 0.060 |
Why?
|
Health Personnel | 1 | 2018 | 3380 | 0.060 |
Why?
|
Cell Adhesion | 1 | 2010 | 3102 | 0.060 |
Why?
|
Electronic Health Records | 2 | 2018 | 4875 | 0.060 |
Why?
|
Risk | 3 | 2012 | 9636 | 0.060 |
Why?
|
Genomics | 1 | 2019 | 5916 | 0.050 |
Why?
|
Mice, Inbred NOD | 2 | 2019 | 1839 | 0.050 |
Why?
|
Lutetium | 1 | 2023 | 38 | 0.050 |
Why?
|
Heterocyclic Compounds, 1-Ring | 1 | 2023 | 68 | 0.050 |
Why?
|
Marital Status | 1 | 2024 | 426 | 0.050 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2024 | 305 | 0.050 |
Why?
|
Female | 19 | 2024 | 397089 | 0.050 |
Why?
|
Mendelian Randomization Analysis | 2 | 2019 | 1037 | 0.050 |
Why?
|
Prospective Studies | 5 | 2024 | 54920 | 0.050 |
Why?
|
Histones | 3 | 2018 | 2592 | 0.050 |
Why?
|
Sequence Analysis | 1 | 2022 | 240 | 0.050 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7599 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2024 | 583 | 0.050 |
Why?
|
Genealogy and Heraldry | 1 | 2021 | 29 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10776 | 0.050 |
Why?
|
Odds Ratio | 3 | 2019 | 9682 | 0.050 |
Why?
|
Nucleotides | 1 | 2023 | 455 | 0.050 |
Why?
|
Dipeptides | 1 | 2023 | 386 | 0.050 |
Why?
|
Nuclear Proteins | 2 | 2013 | 5800 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2018 | 3438 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2015 | 12805 | 0.040 |
Why?
|
Propensity Score | 2 | 2018 | 1962 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2010 | 2952 | 0.040 |
Why?
|
Genetic Markers | 2 | 2019 | 2604 | 0.040 |
Why?
|
RNA, Double-Stranded | 1 | 2021 | 293 | 0.040 |
Why?
|
Penetrance | 1 | 2021 | 384 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2012 | 4936 | 0.040 |
Why?
|
Genes, Neoplasm | 1 | 2021 | 370 | 0.040 |
Why?
|
Fanconi Anemia | 1 | 2021 | 327 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 14154 | 0.040 |
Why?
|
Carcinoma | 1 | 2010 | 2341 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4646 | 0.040 |
Why?
|
Phenotype | 4 | 2020 | 16721 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 564 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2021 | 433 | 0.040 |
Why?
|
Epithelial Cells | 1 | 2010 | 3695 | 0.040 |
Why?
|
Risk Assessment | 3 | 2021 | 24318 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 2010 | 2544 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3666 | 0.040 |
Why?
|
Breast Neoplasms | 2 | 2019 | 21162 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9510 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 710 | 0.040 |
Why?
|
Massachusetts | 1 | 2010 | 8902 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 793 | 0.040 |
Why?
|
Interferons | 1 | 2021 | 716 | 0.030 |
Why?
|
Oncogenes | 1 | 2023 | 1235 | 0.030 |
Why?
|
Europe | 1 | 2024 | 3439 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12558 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2018 | 551 | 0.030 |
Why?
|
DNA-Binding Proteins | 3 | 2023 | 9614 | 0.030 |
Why?
|
Radioisotopes | 1 | 2018 | 517 | 0.030 |
Why?
|
Immunotherapy | 1 | 2012 | 4738 | 0.030 |
Why?
|
Indazoles | 1 | 2018 | 305 | 0.030 |
Why?
|
Immunity | 1 | 2022 | 1003 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 13084 | 0.030 |
Why?
|
Case-Control Studies | 3 | 2024 | 22296 | 0.030 |
Why?
|
United States | 5 | 2024 | 73150 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1623 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1141 | 0.030 |
Why?
|
Income | 1 | 2024 | 1877 | 0.030 |
Why?
|
Efficiency | 1 | 2018 | 477 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2015 | 12092 | 0.030 |
Why?
|
Haplotypes | 2 | 2011 | 2724 | 0.030 |
Why?
|
Gene Amplification | 1 | 2019 | 1090 | 0.030 |
Why?
|
Signal Transduction | 4 | 2021 | 23631 | 0.030 |
Why?
|
Atlases as Topic | 1 | 2016 | 248 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2461 | 0.030 |
Why?
|
Histone Code | 1 | 2015 | 160 | 0.030 |
Why?
|
Pelvis | 1 | 2019 | 738 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2018 | 583 | 0.030 |
Why?
|
Language | 1 | 2024 | 1558 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2018 | 2475 | 0.030 |
Why?
|
Self Efficacy | 1 | 2018 | 643 | 0.030 |
Why?
|
Respiratory Mechanics | 1 | 1998 | 722 | 0.030 |
Why?
|
Binding, Competitive | 1 | 2015 | 1142 | 0.030 |
Why?
|
Social Support | 1 | 2024 | 2191 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2022 | 1901 | 0.030 |
Why?
|
Mice, SCID | 1 | 2019 | 2632 | 0.030 |
Why?
|
Nephrectomy | 2 | 2012 | 949 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2015 | 300 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2058 | 0.030 |
Why?
|
Up-Regulation | 1 | 2022 | 4142 | 0.030 |
Why?
|
Drug Synergism | 1 | 2017 | 1762 | 0.030 |
Why?
|
Introns | 1 | 2015 | 968 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2019 | 1748 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2015 | 525 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 2925 | 0.030 |
Why?
|
Heterozygote | 1 | 2019 | 2791 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 1998 | 848 | 0.030 |
Why?
|
Pulmonary Emphysema | 1 | 1998 | 690 | 0.030 |
Why?
|
Benchmarking | 1 | 2018 | 1058 | 0.020 |
Why?
|
Adolescent | 4 | 2021 | 89184 | 0.020 |
Why?
|
Kinetics | 1 | 2019 | 6333 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 2019 | 2247 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6318 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2460 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2023 | 3407 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2020 | 2708 | 0.020 |
Why?
|
Mice | 4 | 2019 | 82017 | 0.020 |
Why?
|
Program Evaluation | 1 | 2018 | 2505 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3553 | 0.020 |
Why?
|
Animals | 6 | 2021 | 169337 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1913 | 0.020 |
Why?
|
Leukocytes | 1 | 2017 | 2030 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2018 | 2168 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4981 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7574 | 0.020 |
Why?
|
Regression Analysis | 2 | 2015 | 6350 | 0.020 |
Why?
|
Young Adult | 3 | 2021 | 60049 | 0.020 |
Why?
|
Sulfonamides | 1 | 2018 | 1980 | 0.020 |
Why?
|
Phosphorylation | 1 | 2019 | 8326 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4588 | 0.020 |
Why?
|
Cell Survival | 1 | 2018 | 5792 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 362 | 0.020 |
Why?
|
Pain | 1 | 2023 | 5103 | 0.020 |
Why?
|
Child, Preschool | 2 | 2021 | 42650 | 0.020 |
Why?
|
Locomotion | 1 | 1990 | 390 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15455 | 0.020 |
Why?
|
Lipids | 1 | 2019 | 3344 | 0.020 |
Why?
|
Registries | 1 | 2024 | 8379 | 0.020 |
Why?
|
Foreign Bodies | 1 | 1972 | 403 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2018 | 5313 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5764 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3728 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3543 | 0.020 |
Why?
|
Neutrophils | 1 | 2019 | 3785 | 0.020 |
Why?
|
Lymphography | 2 | 1966 | 189 | 0.020 |
Why?
|
Metabolic Networks and Pathways | 1 | 2011 | 798 | 0.020 |
Why?
|
Internet | 1 | 2019 | 3107 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2024 | 11668 | 0.020 |
Why?
|
Lung | 2 | 1998 | 10089 | 0.020 |
Why?
|
Chyle | 1 | 1966 | 19 | 0.020 |
Why?
|
Urinary Fistula | 1 | 1966 | 44 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14784 | 0.020 |
Why?
|
Medical Oncology | 1 | 2018 | 2349 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6277 | 0.020 |
Why?
|
Genetics, Population | 1 | 2010 | 942 | 0.020 |
Why?
|
Organ Specificity | 1 | 2010 | 1967 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10654 | 0.020 |
Why?
|
Extremities | 1 | 1990 | 870 | 0.020 |
Why?
|
Lymphatic System | 1 | 1966 | 252 | 0.010 |
Why?
|
Time Factors | 2 | 2017 | 40272 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2022 | 11918 | 0.010 |
Why?
|
Fistula | 1 | 1966 | 213 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3922 | 0.010 |
Why?
|
Corpus Striatum | 1 | 1990 | 1237 | 0.010 |
Why?
|
Insulin | 1 | 2019 | 6607 | 0.010 |
Why?
|
Blood Glucose | 1 | 2019 | 6430 | 0.010 |
Why?
|
Mepivacaine | 1 | 1963 | 8 | 0.010 |
Why?
|
Logistic Models | 1 | 2018 | 13323 | 0.010 |
Why?
|
Podiatry | 1 | 1963 | 28 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2019 | 19022 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8541 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2011 | 4120 | 0.010 |
Why?
|
Child | 2 | 2021 | 80891 | 0.010 |
Why?
|
Models, Biological | 1 | 2018 | 9493 | 0.010 |
Why?
|
Models, Genetic | 1 | 2012 | 3442 | 0.010 |
Why?
|
Lung Diseases | 1 | 1972 | 1925 | 0.010 |
Why?
|
Anesthesia, Local | 1 | 1963 | 279 | 0.010 |
Why?
|
Aortic Aneurysm | 1 | 1966 | 649 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 13052 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2010 | 3458 | 0.010 |
Why?
|
Infant | 1 | 2001 | 36510 | 0.010 |
Why?
|
Maximal Voluntary Ventilation | 1 | 1998 | 14 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2001 | 15881 | 0.010 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 1998 | 94 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2010 | 4526 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 1964 | 1274 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 1964 | 805 | 0.010 |
Why?
|
Respiratory Muscles | 1 | 1998 | 144 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2015 | 20224 | 0.010 |
Why?
|
Lung Volume Measurements | 1 | 1998 | 382 | 0.010 |
Why?
|
Anesthetics, Local | 1 | 1963 | 1004 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2019 | 12241 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 1964 | 2044 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1964 | 2257 | 0.010 |
Why?
|
Neurons | 1 | 1990 | 9513 | 0.010 |
Why?
|
Incidence | 1 | 2009 | 21544 | 0.010 |
Why?
|
Exercise Test | 1 | 1998 | 2186 | 0.010 |
Why?
|
Skin Physiological Phenomena | 1 | 1990 | 193 | 0.010 |
Why?
|
Electrodes | 1 | 1990 | 617 | 0.000 |
Why?
|
Electrophysiology | 1 | 1990 | 1266 | 0.000 |
Why?
|
Angiocardiography | 1 | 1966 | 149 | 0.000 |
Why?
|
Electric Stimulation | 1 | 1990 | 1743 | 0.000 |
Why?
|
Urine | 1 | 1966 | 363 | 0.000 |
Why?
|
Diagnostic Errors | 1 | 1972 | 1280 | 0.000 |
Why?
|
Radiography | 1 | 1972 | 6993 | 0.000 |
Why?
|
Statistics as Topic | 1 | 1966 | 2363 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1972 | 13020 | 0.000 |
Why?
|
Rats | 1 | 1990 | 23835 | 0.000 |
Why?
|